Dr Reddy’s Laboratories recorded its worst weekly stock performance in three years after announcing disruptions in the supply of its generic semaglutide drug. The company said production of new batches had been halted due to an impurity issue in the active ingredient, with supplies expected to remain unavailable in India and disrupted in Canada until […]Continue Reading
